Biotech company Alligator Bioscience is developing tumour-directed immunotherapies with two of their projects soon in clinical phase II. Recently, the company announced two new additions to their management team, Peter Ellmark as CSO and Christina Reimer as CMO. They both visited BioStock’s studio at Medicon Village in Lund to talk about their new roles, ongoing projects and what lies ahead for the company.
Watch the interview with Alligator Bioscience’s CSO Peter Ellmark and CMO Christina Reimer below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.